Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Slides
Videos-PodcastsVideos & Podcasts

Quicksearch

ECCO IBD Curriculum

6.6. Appreciates common side effects and complications of therapy, their frequency and how to manage them.
Exit StrategiesECCO e-Learning
Year: 2017
Authors: Johan Burisch, Ren Mao, Edyta Szymanska, Glen Doherty

This course has been developed for gastroenterologists, surgeons, paediatricians, pathologists and other interdisciplinary medical experts interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to provide evidence-based guidance for clinical practice so that physicians can make informed decisions in partnership with their patients regarding their optimal exit strategies.

After this course you will:

  • To recognise risks, benefits and timing of stopping anti-TNF used as monotherapy or in combination with IM in IBD.
  • To know optimal monitoring following withdrawal of biologic therapy

Crohn's disease: Perianal disease e-Coursee-Course
Year: 2020
Authors: Federica Furfaro, Kostas Katsanos, Pascal Juillerat, Pierre Ellul

This course has been developed by physicians who had recently participated in the writing of the ECCO Crohn's disease consensus Guidelines. This course is intended for those who are interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to Perianal disease in order to improve patient outcomes.

After this case you will:

  • To appreciate the Crohn’s disease natural history
  • To appreciate the rationale behind specific treatment decisions
  • To understand the right investigations to prescribe to Crohn’s disease patient in specific settings
  • To learn appropriate clinical management of Crohn’s disease patients with perianal involvement

Luminal Crohn's disease e-Coursee-Course
Year: 2020
Authors: João Sabino, Bram Verstockt, Kostas Katsanos, Pascal Juillerat, Pierre Ellul

This course has been developed by physicians who had recently participated in the writing of the ECCO Crohn's disease consensus Guidelines. This course is intended for those who are interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to Luminal disease in order to improve patient outcomes.

Upon completion of this case you will:

  • Know the evidence for induction of remission in mild-to-moderate Crohn’s disease;
  • Know the evidence for maintaining remission in  Crohn’s disease;
  • Know the evidence on how to react upon disease flares, immediately after induction therapy or during maintenance therapy; 
  • Understand the benefits and risks of several medical therapies;
  • Achieve familiarity how to use immunomodulatory agents in mono- or combination therapy;
  • Achieve familiarity how to monitor Crohn’s disease patients who initiated medical therapy or who underwent surgery;
  • Recognise indications for surgical management.

Skin side-effects of Anti-TNFSkills Videos
Year: 2019
Authors: Henit Yanai
Anaemia in Crohn's Disease: From the nurse's perspective e-Coursee-Course
Year: 2016
Authors: Janette Gaarenstroom and Palle Bager

This sub-course is adapted from the course "Anaemia in Crohn's Disease”, which was developed for gastroenterologists, surgeons, paediatricians, pathologists and other interdisciplinary medical experts interested in Inflammatory Bowel Disease(s) (IBD).  This course has been developed for all nurses who care for patients with IBD. For more advanced knowledge, please follow the main e-learning case, "Anaemia in Crohn's Disease”.

The aim of this e-learning activity is to increase competence and knowledge with regard to the management and care of patients with Crohn's Disease and anaemia in order to improve patient outcomes.

Upon completion of this activity learners will:

  • Have basic knowledge about anaemia in Crohn's Disease patients
  • Have basic knowledge about the symptoms and treatment of anaemia in Crohn's Disease patients


UC Update e-Coursee-Course
Year: 2016
Authors: Gianluca Pellino, Tim Raine, Dominik Bettenworth, Johan Burisch, Kristzina Gecse, Pieter Hindryck, Antonio López-Sanromán

This course is designed for gastroenterologists, surgeons, paediatricians, pathologists and other interdisciplinary medical experts interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to the prediction, diagnosis and management of Ulcerative Colitis (UC) patients and to harmonise diagnostics and treatment in order to improve patient outcomes.

Upon completion of this activity learners will:

  • Have insights into the basic epidemiology of ulcerative colitis
  • Know current treatment options for severe ulcerative colitis, including colectomy
  • Be able to use ciclosporin correctly in severe ulcerative colitis
  • Understand when to order thiopurine methyltransferase (TPMT) activity when starting azathioprine

Interactive Case - Anaemia - e-Coursee-Course
Year: 2014
Authors: Stephan Vavricka, Dominik Bettenworth

This course is designed for gastroenterologists, surgeons, paediatricians, pathologists and other interdisciplinary medical experts interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to the management of CD patients and to harmonise diagnostics and treatment of anaemia in order to improve patient outcomes.

Upon completion of this activity learners will:

  • Know how to diagnose anaemia in Crohn's disease (CD) patients
  • Be able to adequatly treat iron deficiency anaemia in CD patients

'Mainstream' biologicals: When to use?6th Basic ECCO: EduCational COurse for Industry
Year: 2022
Authors: Jean-Frédéric Colombel
'Older' medication: Still useful?6th Basic ECCO: EduCational COurse for Industry
Year: 2022
Authors: Uri Kopylov
Summary content

An overview of the use of 5-ASA, steroids and immunomodulators in IBD 

Anti-IL 12/2320th IBD Intensive Course for Trainees
Year: 2022
Authors: Marc Ferrante
Summary content

Educational objectives:
1. To understand the role of IL-12 and IL-23 in the development of IBD
2. To review the pivotal UNITI and UNIFI trials
3. To review the place of ustekinumab in IBD therapy
4. To have an overview on practical modalities of ustekinumab therapy
5. To get insight in the anti-IL23 drugs that are in development

Anti-integrins20th IBD Intensive Course for Trainees
Year: 2022
Authors: James Lindsay
Summary content

Educational objectives:
1. To understand the mechanism of action of vedolizumab and other anti interns
2. To review the key phase III clinical data
3. To highlight studies from real world cohort and discuss the safety profile of Vedolizumab
4. To understand how to position Vedolizumab in clinical practice

Complications associated with anti-TNF therapy20th IBD Intensive Course for Trainees
Year: 2022
Authors: Yehuda Chowers; Shomron Ben-Horin
Summary content

Learning Objectives - Risks associated with anti-TNF treatments
1. Hypersensitivity reactions
2. Dermatological adverse effects with anti‐TNF therapy
3. Autoimmune‐like disorders
4. Infections and management strategies
5. Malignancy
6. Patients’ selection for anti TNFs vs other biologics

JAK inhibitors20th IBD Intensive Course for Trainees
Year: 2022
Authors: Silvio Danese
Summary content

Educational objectives:
1. Learn about the mechanisms of action of tofacitinib
2. Understand the clinical and endoscopic efficacy of tofacitinib in UC
3. Discuss the safety profile of tofacitinib

Safety after all6th Basic ECCO: EduCational COurse for Industry
Year: 2022
Authors: Laurent Beaugerie
Summary content

The educational objectives of the presentation are:
1. To understand that the choice of long-term treatment of IBD must take into account the benefit-risk balance of old and new IBD drugs
2. To review the most important aspects of IBD drug-induced cancers and serious infections
3. To understand that in most cases benefits outweigh risks, and that patients should not be undertreated
4. To understand, based on the example of tofacitinib, that it is important keep prudent with recently approved IBD drugs until powered data is available

After introducing the concept of benefit-risk balance, the presentation will review the three major aspects of IBD drug potential complications: drug-class specific complications, malignancies, and serious infections, including opportunistic infections.  A special focus will be made on thiopurine-induced lymphomas, thiopurine and anti-TNF-induced serious bacterial and viral infections, and how to manage these risks. We will then discuss the difficult choice of immunosuppressants in frail and older patients, based on drug-class specific safety data. Finally, using the example of tofacitinib, we will illustrate the importance of prescribing with caution recently approved drugs, until we have extensive safety data.

CD Management11th N-ECCO School
Year: 2020
Authors: Marieke Pierik
SteroidsEducational Audio Podcast
Year: 2020
Authors: Gionata Fiorino
TofacitinibEducational Audio Podcast
Year: 2020
Authors: Konstantinos Karmiris
Transatlantic Talking Heads: Opioids and Pain Management Transatlantic Talking Heads
Year: 2020
Authors: James Lindsay, David Rubin, Jane Andrews
UC Management11th N-ECCO School
Year: 2020
Authors: Mark Samaan
Anti-TNFEducational Audio Podcasts
Year: 2019
Authors: Christian Maaser